Pending Medicare Fee-Schedule Selection For Gene Tests Has Significant Implications – Consultant
This article was originally published in The Gray Sheet
Executive Summary
Which payment system should incorporate new molecular diagnostic codes? CMS’ decision could have unsettling results for some gene test makers.